CTCs和CTMs在局部晚期鼻咽癌预后判断中的临床应用
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Clinical Application of CTCs and CTMs in prognosis of locally advanced nasopharyngeal carcinoma
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    探讨外周血中循环肿瘤细胞(CTCs)和循环肿瘤癌栓(CTMs)的动态计数变化在局部晚期鼻咽癌患者预后判断中的价值。方法 纳入四川大学华西医院2018年6月~2021年1月收治的38例局部晚期鼻咽癌患者,分别收集患者治疗前、诱导化疗结束后1周和调强放射治疗结束1月及1年后的肘静脉血,采用差相富集-肿瘤标志物免疫荧光染色-荧光原位杂交(SE-iFISH)技术检测CTCs和CTMs。分析CTCs和CTMs与临床病理特征、血清EBV-DNA表达水平和放疗靶区参数的相关性。进一步分析诊疗过程中CTCs各个亚型的变化与诊疗效果的关系。结果 治疗前 CTCs的阳性率为94.74%(36/38), CTMs的阳性率为10.53%(4/38),其中PD-L1阳性率5.26%(2/38)。CTCs和CTMs阳性检出率与鼻咽癌患者的性别、年龄、ECOG评分、TNM分期、血清EBV-DNA表达水平均无相关性(P>0.05)。CTCs和CTMs基线与肿瘤原发灶靶区(GTVnx)、淋巴结靶区(GTVnd)及大体肿瘤体积(GTV)均无相关性(P=0.478,P=0.647,P=0.077;P=0.254,P=0.687,P=0.082)。在后期随访的20 例患者中(17 例患者出现CR、PR或SD,3 例患者治疗后出现PD),获得CR、PR或SD组,CTCs数目在治疗前为(9.8±5.7)个,治疗后下降为(2.4±6.2)个;CTMs数目在治疗前为(2.9±1.2)个,治疗后下降至(1.4±0.2)个(P<0.05);3 例PD组的患者外周血中,CTCs数目在治疗前为(14.2±3.9)个,治疗后下降为(3.7±4.2)个(P<0.05);CTMs数目在治疗前为(2.9±1.2)个,治疗后下降至(1.4±2.2)个(P<0.05)。同时,治疗后患者外周血CTCs和CTMs比例和PD-L1阳性的CTCs数量均下降,各亚型CTCs下降从高到低依次分别是三倍体、四倍体、≥五倍体。结论 外周血CTCs和CTMs计数动态监测可作为局部晚期鼻咽癌患者预后判断的重要指标

    Abstract:

    To investigate the relation between the dynamic counts of Circulating Tumor Cells (CTCs)/Circulating Tumor Microembolis (CTMs) in peripheral blood and the prognosis of local advanced nasopharyngeal carcinoma (NPC). Methods Thirty-eight local advanced NPC patients were enrolled. Blood was collected at time points of before treatment, after neo-chemotherapy, 1 month and 1 year after intensity modulated radiotherapy (IMRT), respectively. CTCs/CTMs were detected by differential enrichment-tumor marker immunofluorescence staining-fluorescence in situ hybridization (SE-iFISH) method. Besides the relations among baseline CTCs/CTMs, clinicopathological features, serum EBV-DNA expression level and radiotherapy target parameters was analyzed, finally the relationship among CTCs, CTMs and prognosis was detected.Results The positive rates of CTCs and CTMs before treatment were 94.74% (36/38) and 10.53% (4/38), respectively, in which 2 patients presented PD-L1 (2/38).No significant differences among CTCs/CTMs baseline, gender, age, ECOG score, TNM stage and serum EBV-DNA expression in local advanced NPC patients were detected(P=0.337, P=0.502, P=0.090, P=0.076, P=0.398, respectively),and no relation among CTCs/CTMs baseline and primary tumor target (GTVnx), lymph node target (GTVnd) and gross tumor volume (GTV) were found (P=0.478, P=0.647, P=0.077; P=0.254, P=0.687, P=0.082, respectively). Meanwhile, in total, 20 patients (DCR=85% and PD rate=15%) was obtained in follow-up. The number of CTCs and CTMs were (9.8±5.7) and (2.9±1.2) before treatment and decreased to (2.4±6.2) and (1.4±0.2) after treatment, respectively. Furthermore, not only the number of CTCs and CTMs of 3 PD patients was (14.2±3.9) and (2.9±1.2) before treatment and decreased to (3.7±4.2) and (1.4±2.2) after treatment, respectively, but also the CTCs/CTMs ratio and PD-L1 positive on CTCs decreased, especially was triploid, tetraploid and ≥pentaploid CTCs subtype.Conclusion Monitoring peripheral blood CTCs, CTMs and CTCs/CTMs ration could be a prognosis potential indicator of local advanced NPC.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-02-17
您是第位访问者
版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司